Market capitalization | $8.94m |
Enterprise Value | $6.07m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 31.95 |
P/S ratio (TTM) P/S ratio | 47.05 |
P/B ratio (TTM) P/B ratio | 1.02 |
Revenue growth (TTM) Revenue growth | -68.09% |
Revenue (TTM) Revenue | $190.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Cyclerion Therapeutics,Inc.:
1 Analyst has issued a forecast Cyclerion Therapeutics,Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 0.19 0.19 |
69%
69%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -5.93 -5.93 |
72%
72%
|
EBIT (Operating Income) EBIT | -5.93 -5.93 |
72%
72%
|
Net Profit | -5.28 -5.28 |
80%
80%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Regina Graul |
Employees | 1 |
Founded | 2018 |
Website | www.cyclerion.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.